{"name":"Galectin Therapeutics Inc.","slug":"galectin-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":14290000,"netIncome":-30836000,"cash":17720000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxQUEFBSV9lQWpxV055LWxfMklZc25mSkcyQVRqSWY0X0F6WFhTajJsQUI0MUhGM0pwdHllZk5SWVJqZl9RSUFFMDV1MWRPRmVWMDl2ODNFcVhUMXQ5UG5Fb282QUozRkJ0WjhxT0RhNGlBUWFhU2lsMmFlR2VGdWNBNWxJcjRPSGd5a29GdVd0UXJIUkhHazhtRUdwU0dKaEJLOG5NM0J1bUJrazVEcmxJa2dBYXkxa2hQNjhsSw?oc=5","date":"2026-03-31","type":"pipeline","source":"stocktitan.net","summary":"Galectin Therapeutics (NASDAQ: GALT) launches $32.5M ATM; 3% agent fee - stocktitan.net","headline":"Galectin Therapeutics (NASDAQ: GALT) launches $32.5M ATM; 3% agent fee","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxOekdGNDZReUktU0k1VUEwSTNERXJTTzUzY0Ruck9NVXVkS0g0RVJKbHlTZWZ5QkJGZThSQ0U0bzZ6Yk5sbUF1bmhTZnE3Wnl4R1NDMC1CR2hDRjNuVTI0cFVscnUtendJTEdVYzJ5WU41UWp2QnAxMXhlbjI5MXBPT3dOVzlubjhKNW1wQXY1WWRlUy03Y2ttUW43M3YxUWRVcjRwZFJlQl9PVHdXRG9EX3VR?oc=5","date":"2026-03-31","type":"trial","source":"stocktitan.net","summary":"NAVIGATE MASH data and funding risks at Galectin (NASDAQ: GALT) - stocktitan.net","headline":"NAVIGATE MASH data and funding risks at Galectin (NASDAQ: GALT)","sentiment":"neutral"},{"date":"2026-03-31","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-31","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-17","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxNNnczaW9XWk5YSmxWTVhtTllZWnF1MV9xdTBuTmxYUG5GejZ2NFZEa0FydkIyeG5NU3RoNGc0UmJ1VzhtbGFIVGFvQVByRzM1Rk1JNU9KS3BVVzZfQXhBZG1IaGtMU3c2OXVKbENKNHpibGtjX0hTWGpWbk54aTdTMnNtdTJ3LWd6UE16YWhFalplTlllRFUzMXRMYTFTeVpoYnIwMVAyOGdmUWNnc3dZeDFwNA?oc=5","date":"2026-03-05","type":"pipeline","source":"Stocktwits","summary":"Why Did GALT Shares Plummet Over 30% Today? - Stocktwits","headline":"Why Did GALT Shares Plummet Over 30% Today?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1wFBVV95cUxOOHFCTzk0OEp0RzVqU216Vm1OVzJjdmVBeWRlSVM1OXlucmpQenRzREk1b1VCZGlCMW1OUGQtYkpEclFteTlscTJzbUdhWHFlTUxTem5JQm5QRjJ1WkdCTnlTczRNNmVBeG9nZ3BESG9Od1h2c1B4NnlEZVNPcFpSWWRKQjJ5d3E4UHVtY2VPTHlqR19Ib0h0SEwxQ0lLV251MVZJR0xBdkowTVZGci1kNXlCWUVQSEluZWY3bUlYMzNReDdXY3I3b1hUaXhsUFVGejhsQ2xPYw?oc=5","date":"2026-03-03","type":"pipeline","source":"The Globe and Mail","summary":"Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail","headline":"Wall Street Analysts Are Bullish on Top Healthcare Picks","sentiment":"neutral"},{"date":"2026-01-21","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxQeXZ6SnJKRElYd0VkdUpkaF9lc3U5dzlJQ1FDRmN2eU9lT2s4OXQyZTVCY0x6ODVWZDhqZnhhMmZXblVNZFZmcGgxcFByUGk3UzVKQ0NLX212djkzanBmM3R5QklDYU5nYXpQQ0hxMFhHcFAyR3lJaVVMNThsc291WjQtZDRhWVBPLUV3Q2FBS3c0NkxJb1ltQ3dMZ1pVbV9aN3hQYzJQcXc?oc=5","date":"2026-01-05","type":"pipeline","source":"Investing News Network","summary":"Top 5 Small-cap Pharma Stocks (Updated January 2026) - Investing News Network","headline":"Top 5 Small-cap Pharma Stocks (Updated January 2026)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxOVTVYX3ZXME1oWDZWUk40Q2FpZ28wQ0hEUmdtX0hLbzl2aUttR3FWRlRxbDdNdW9XN25YWFlGam1wQVJpWFpka2J0S1ZfYWU4VlU3Zi1NZ3RqZzdBei01SGlpekFUdEhpSl8tSUxDUEhNa0ZmTkQ4VUw0R3RUQXBDX3dnZFlxRjJ1VlFlaF9mWVlzRTFNenQyYXpRRTQxSXc2aWliU2NIZmVIV2ZJdDdoUHQxSEFnTjlOMWVnOVhpdlE?oc=5","date":"2025-12-24","type":"regulatory","source":"Seeking Alpha","summary":"Galectin Therapeutics: Runway With Convertible Financing But Dilution Overhang Remains - Seeking Alpha","headline":"Galectin Therapeutics: Runway With Convertible Financing But Dilution Overhang Remains","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxQZnUxMHQ0V1VpcWhhQlZxV0kzWlJfc013QjFHUF9EQW51VmM2TTNYcUs0d3B0Smk4VmxOWkRNVGhtMm9tV2FYcVFGQ29TOWx5M0pYNmw0VjF1V25QWnUzZ3h5ZE1fUmNiY01mNkM4X0V2QmhIUFlsWWZYQXRrd1ZBWjByUllReVVPQm1wMF9UYmRlU2pNZjJjZjlMRWZtNS1qVUxKdmJCZldfbzFCUlVGcmxWUXlDOXZ4?oc=5","date":"2025-12-19","type":"pipeline","source":"stocktitan.net","summary":"New funding keeps potential liver cirrhosis treatment on track to 2027 - stocktitan.net","headline":"New funding keeps potential liver cirrhosis treatment on track to 2027","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxPOTlfS0NKRk8wYVdacE5PMDQ0U21wTllHNjBKeGV5RFVMY2tHNFQ4VHptdW1EUDJnel9ocFhqbnNhbm1BRzBJRldsYi1SZU1KWmRfV19XVjFabWFkLV9HWHRHbVp2ckhqUGRmSnBLUXlmbDB6bV83UjNIZnFUZUNPWE5xcjlvT0xyODNaN1lwSmVmdGpoZFdmTDJsSENzOGd5UExMS0pDejZVeGFjR1NzTDBMMnQ?oc=5","date":"2025-08-25","type":"deal","source":"Seeking Alpha","summary":"Galectin: With Time Ticking, A Partner Is Needed To Revitalize MASH Program - Seeking Alpha","headline":"Galectin: With Time Ticking, A Partner Is Needed To Revitalize MASH Program","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgJBVV95cUxPLXA1VDlORlNsSWJ0akRIM1BDUldVcGZuRzJhNjkzMzhVUHhfMHQ4d04tMGtERDlUb0VvMmRHSHdwU3V5ZUxuM1dQb3RLV2xsbUdValpqYTdLbDNtWWZMMVhQZE9maW45V0xleG9pbjhhMFo1RW13cEhBTG9KcTVxRWR1NmVCSG9ZVEgwdVZUMVdGM2p6N2hoYm9zbmpvUWZQUmpwVmQ4blcwQzZMVUhndEQyQ3B5QTJuSi1MX0dMdlo1SXZCbFNZUllpdUpOekJKakJ5TUV6Qm1DSTc2OVBUUlo4eVhmOFJCckpyakpyeXFqVjRCQW9sQTRhd1Y0emtuR1ZrdVJXc2pMV1h1N2VYTl81dHQzalZGQ0xZRXFpSFlwdU53M3c?oc=5","date":"2025-05-13","type":"pipeline","source":"PR Newswire","summary":"Liver Fibrosis Market to Witness Rapid Growth at a CAGR of ~24% During the Forecast Period (2025-2034) with Emerging Treatment Options | DelveInsight - PR Newswire","headline":"Liver Fibrosis Market to Witness Rapid Growth at a CAGR of ~24% During the Forecast Period (2025-2034) with Emerging Tre","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxNMWwxRV9ySzlJYWtMeWllcFZlX3NrczVJU2FlYlR2Q1lwNDFyWnpZbHZwc1BreVdBVlcxbTYzTnNFTENQVy04YjVVVVV3OHlIa1dLQkllSEp4aVZ5ZTd5TUhWSmFUMFNaZnZiaTJuUllXdHVKTERoX0F1SlprTjhVakpXMUFNWUZvaDBvaDVPcGxUa0o0c3puVmZSWDhxaEh0RlZTRUxYOTB4OGQzVUtIZGdFWUJETXV0VGNzSEJyRTZrQjVoV0E?oc=5","date":"2024-12-15","type":"trial","source":"insiderfinancial.com","summary":"Short Mafia Attacking Galectin Therapeutics (NASDAQ : GALT) Ahead of Planned Year-End Readout - insiderfinancial.com","headline":"Short Mafia Attacking Galectin Therapeutics (NASDAQ : GALT) Ahead of Planned Year-End Readout","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxQWHM2YzBtOTFyMEpNNGx0MlkwdkhxTVdWODZpcU1XQV9URnFmemlLUTR6YVI3aUtsUWhfbXNBNUNTbDM4d0tMR0pZbjVmeGpYV0tIdzM1S09ZSnZGQ2M0VEJqcHlaaDV6bDktbWVMYkV2Q0dfUXg2RkN5OGJqR2lQRDVtd2lhV19ZVS1iMFR6WlhqU3M2RTFBa2w3V2dRdEd5dGhQUWZ1MWNJSmp4ajlKNVZ1bkxFZw?oc=5","date":"2024-08-26","type":"deal","source":"Investing.com","summary":"Galectin Therapeutics executive buys $8,050 in company stock - Investing.com","headline":"Galectin Therapeutics executive buys $8,050 in company stock","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":14290000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-30836000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":17720000,"cashHistory":[],"totalAssets":19532000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}